Fate Therapeutics refiles Leerink stock sale plan under new $100 million shelfNov 12FinancingFate TherapeuticsUpdated
Fate Therapeutics gives Q3 2026 update on lupus CAR T program and FT839 trial sitesNov 10Regulatory decisionAutolus Therapeutics plcFate TherapeuticsUpdated
Fate Therapeutics gets $15 million CIRM grant for lupus nephritis CAR T trialSep 28Clinical readoutFate TherapeuticsFT819
Fate Therapeutics doses first lupus nephritis patient in Phase 2 FT819 trial, clears FT839 INDAug 13Quarterly updateFate TherapeuticsFT819